Annual revenue of CanSino Biologics Inc. 2017-2023

Published by
Wenyi Zhang,
Sep 4, 2024

In 2023, the Tianjin-based Chinese vaccine company Cansino Biologics Inc. reported annual revenue of 357.08 million yuan, representing an drop of more than 65 percent from the previous year. The company generated little revenue between 2017 and 2019 and suffered from losses before the COVID-19 pandemic. More than 70 percent of the CanSino's revenue in 2021 came from the international market, thanks to the export sales of Convidecia, the company's single-dose COVID-19 vaccine.

Annual revenue of CanSino Biologics Inc. between 2017 and 2023 (in million yuan)

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

March 2024

Region

China

Survey time period

2017 to 2023

Supplementary notes

* Only audited revenue figures are shown in the original report. The unaudited revenue for 2019 is 2.28 million yuan.

Figures have been rounded.

One yuan equals to approximately 0.14 U.S. dollars and 0.13 euros (as of September 2024).

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Chinese COVID-19 vaccines "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Chinese COVID-19 vaccines

Overview

6

Sinovac

6

Sinopharm and CanSino

6

Domestic adoption

5

Exports

5

Further Content: You might find this interesting as well

Topics

Chinese COVID-19 vaccinesCoronavirus COVID-19 in ChinaPharmaceutical industry in ChinaVaccine industry in ChinaCoronavirus disease (COVID-19) pandemic
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.